He Yan, Chen Jun, Peng Xingchen, Xia Yanli, Su Yonglin
Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China.
Department of Ophalmology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China.
Cancer Cell Int. 2021 Nov 27;21(1):626. doi: 10.1186/s12935-021-02329-5.
Controversial findings have been reported in the impact of speckle-type POZ protein (SPOP) on clinicopathological features and prognosis in diverse cancers. We conducted this meta-analysis to confirm whether SPOP was an effective biomarker to predict clinical stage, cancer differentiation and survival.
We searched studies published before June 2021 through Medline, Embase, the Cochrane library register of controlled trials and Wanfang databases. The corrections of SPOP expression with expression disparity, tumor differentiation, clinical stage and survival were analyzed.
Our meta-analysis found that higher expression of SPOP was significantly associated with earlier clinical stage, well differentiation and better overall survival. Subgroup analysis showed that the SPOP expression of adjacent tissue was significantly higher than that in cancer tissues of prostate and liver. However, renal cancer presented improved expression of SPOP in cancer tissue.
SPOP has the potential function to act as a novel and effective biomarker for cancer diagnosis and prognostic stratification.
关于斑点型POZ蛋白（SPOP）对多种癌症的临床病理特征及预后的影响，已有一些存在争议的研究报道。我们进行了这项荟萃分析，以确定SPOP是否为预测临床分期、癌症分化及生存情况的有效生物标志物。
我们通过Medline、Embase、Cochrane对照试验图书馆注册库及万方数据库检索了2021年6月之前发表的研究。分析了SPOP表达与表达差异、肿瘤分化、临床分期及生存情况之间的关系。
我们的荟萃分析发现，SPOP的高表达与更早的临床分期、良好的分化及更好的总生存期显著相关。亚组分析显示，前列腺和肝脏的癌旁组织中SPOP表达显著高于癌组织。然而，肾癌的癌组织中SPOP表达有所升高。
SPOP具有作为癌症诊断及预后分层的新型有效生物标志物的潜在功能。
